Stable Formulations of Programmed Death Receptor 1 (PD-1) Antibodies and Hyaluronidase Variants and Fragments Thereof and Methods of Use Thereof

A formulation comprising:

• a) about 20 mg/mL to about 200 mg/mL of an anti-human PD-1 antibody, or antigen binding fragment thereof;
• b) about 0.0009-0.050 mg/ml of a PH20 variant or fragment thereof;
• c) about 5 mM to about 20 mM buffer;
• d) about 3% to about 10% weight/volume (w/v) of a non-reducing dissacharide selected from the group consisting of sucrose and trehalose;
• e) about 0.005% to about 0.10% (w/v) non-ionic surfactant;
• and, optionally
• f) about 1 mM to about 30 mM anti-oxidant.